| Realtime | Geld | Brief | Zeit |
|---|---|---|---|
| 0,970 | 1,060 | 15:10 |
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| PROMIMIC Aktie jetzt für 0€ handeln | |||||
| 06.05.25 | Curiteva & Promimic - Bonded by Innovation | 247 | ACCESS Newswire | HUNTSVILLE, ALABAMA / ACCESS Newswire / May 6, 2025 / Curiteva, a leader in 3D-printed Trabecular PEEK implant technology, is pleased to announce an expanded partnership with Promimic, pioneers in nanotechnology... ► Artikel lesen |
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| MEDTRONIC | 74,26 | -0,62 % | Future Market Insights: Global Weight Loss and Obesity Management Market | 12.8% CAGR Growth Trajectory | Asia Pacific, North America Lead | Novo Nordisk, Eli Lilly, Medtronic Drive Integrated Care Evolution | NEWARK, Del., April 9, 2026 /PRNewswire/ -- According to the latest analysis by Future Market Insights, the global weight loss and obesity management market is undergoing a transformative... ► Artikel lesen | |
| HCA HEALTHCARE | 421,30 | -0,24 % | Cantor Fitzgerald reiterates HCA Healthcare stock rating at Overweight | ||
| LANTHEUS | 70,50 | +0,43 % | Lantheus Holdings, Inc.: Lantheus Announces FDA Approval of PYLARIFY TruVu (piflufolastat F 18) Injection | New formulation of its widely-used U.S. market-leading PSMA PET imaging agent combines thediagnostic performance of PYLARIFY (piflufolastat F 18) with the potential for larger batches and greater... ► Artikel lesen | |
| ENVISTA | 23,200 | 0,00 % | Envista Holdings Corporation: Envista Reports Fourth Quarter 2025 Results | BREA, Calif., Feb. 5, 2026 /PRNewswire/ -- Envista Holdings Corporation (NYSE: NVST) today announced results for the quarter ended December 31, 2025.
"With our... ► Artikel lesen | |
| CAREDX | 14,800 | -1,33 % | CareDx (CDNA) Launches AI-based Platform VANTx | ||
| SYNEOS HEALTH | - | - | AvePoint, Inc.: Research From AvePoint and Omdia Reveals Governance and Compliance as the Leading AI Adoption Barrier Among MSPs | ||
| GT BIOPHARMA | 0,383 | 0,00 % | GT Biopharma, Inc.: GT Biopharma Reports Full Year 2025 Financial Results | Phase 1 trial evaluating GTB-3650 TriKE- continues to actively enroll, with the next update anticipated in Q3 2026 following completion of enrollment in dose Cohort 5 Phase 1 basket trial evaluating... ► Artikel lesen | |
| CARMAT | 0,049 | 0,00 % | XFRA DELETION OF INSTRUMENTS FROM BOERSE FRANKFURT - 24.03.2026 | The following instruments on Boerse Frankfurt do have their last trading day on 24.03.2026.Die folgenden Instrumente in Boerse Frankfurt haben ihren letzten Handelstag am 24.03.2026.ISIN NameCA4013392051 GUARDIAN... ► Artikel lesen | |
| CHEMOMETEC | 43,280 | +0,65 % | Chemometec A/S: Adjustment of guidance for 2025/26 | ANNOUNCEMENT NO. 303 24 March 2026 Adjustment of guidance for 2025/26 Over the past period, ChemoMetec's most important market, the North American market for cell and gene therapy, has been affected... ► Artikel lesen | |
| DEVYSER DIAGNOSTICS | 7,180 | -0,28 % | Devyser Diagnostics AB: Devyser announces that Chief Commercial Officer will leave the company | Devyser Diagnostics AB today announces that the company's Chief Commercial Officer (CCO), Theis Kipling, has decided to leave Devyser to take up a position with another company.
"During Theis' time... ► Artikel lesen | |
| ARRAIL GROUP | 0,203 | -100,00 % | ARRAIL GROUP (06639): CONNECTED TRANSACTION IN RELATION TO AMENDMENT TO THE LOAN AGREEMENT | ||
| POLAREAN IMAGING | 0,001 | -100,00 % | XFRA DELETION OF INSTRUMENTS FROM BOERSE FRANKFURT - 29.12.2025 | The following instruments on Boerse Frankfurt do have their last trading day on 29.12.2025Die folgenden Instrumente in Boerse Frankfurt haben ihren letzten Handelstag am 29.12.2025ISIN NameAU0000111395 PROSPECH... ► Artikel lesen | |
| ALIGNMENT HEALTHCARE | 21,280 | 0,00 % | Alignment Healthcare (ALHC) Soars 16% on Medicare Reimbursement Hike | ||
| FRESENIUS MEDICAL CARE | 38,910 | -1,87 % | EQS-CMS: Fresenius Medical Care AG: Veröffentlichung einer Kapitalmarktinformation | EQS Zulassungsfolgepflichtmitteilung: Fresenius Medical Care AG
/ Bekanntmachung nach Art. 5 Abs. 1 lit. b) der Verordnung (EU) Nr. 596/2014
Fresenius Medical Care AG: Veröffentlichung... ► Artikel lesen | |
| PROGYNY | 17,170 | 0,00 % | Progyny, Inc. Announces Third Quarter 2025 Results | Reports Revenue of $313.3 Million, Reflecting 9.3% GrowthRaises Full Year Guidance to Reflect Continued Strength in Member EngagementSelling Season Yields Over 80 New Clients, 900,000 New Lives, and... ► Artikel lesen |